1y return+62.7%S&P 500 +20.9%
3y return+93.4%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2021: $197 against $157 in the S&P 500.2
Knott David M JrS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| GOOGAlphabet Inc-Cl C | $32.3M | 17.1% | |
| APOApollo Global Management, Inc. | $26.6M | 14.1% | |
| SNDXSyndax Pharmaceutical, Inc. | $9.6M | 5.1% | +3.6% |
| XERSXeris Biopharma Holdings, Inc. | $8.4M | 4.4% | |
| TVTXTravere Therapeutics, Inc. | $8.4M | 4.4% | +4.7% |
| PTGXProtagonist Therapeutics, Inc | $7.7M | 4.1% | |
| BBIOBridgebio Pharma, Inc. | $6.9M | 3.7% | +3.2% |
| IOVAIovance Biotherapeutics, Inc. | $6.7M | 3.5% | |
| Alkermes PLCCUSIP G01767105 | $6.4M | 3.4% | +1.5% |
| JPMJPMorgan Chase & Co. | $5.9M | 3.1% | −7.1% |
| JAAAJanus Henderson AAA CLO ETF | $4.7M | 2.5% | |
| LPL Financial Holdings Inc.CUSIP 52012V100 | $4.6M | 2.5% | |
| COGTCogent Biosciences Inc. | $4.3M | 2.3% | +6.8% |
| TGTXTG Therapeutics, Inc. | $3.7M | 1.9% | −25.7% |
| CLSTCatalyst Pharmaceuticals, Inc. | $3.6M | 1.9% | New |
| AGIOAgios Pharmaceutical, Inc. | $3.5M | 1.9% | +2.1% |
| VRDNViridian Therapeutics, Inc. | $3.3M | 1.8% | |
| RLMDRelmada Therapeutics, Inc. | $3.1M | 1.6% | +2.7% |
| RCUSArcus Biosciences, Inc. | $2.5M | 1.3% | |
| Cybin IncCUSIP 23256X407 | $2.4M | 1.3% | +5.7% |
| XBISPDR S&P Biotech ETF | $2.4M | 1.3% | |
| RZLTRezolute, Inc. | $1.9M | 1.0% | |
| ABAllianceBernstein Holding L.P. | $1.7M | 0.9% | |
| MDGLMadrigal Pharmaaceuticals, Inc. | $1.6M | 0.9% | +50.0% |
| ATRCAtriCure, Inc. | $1.4M | 0.8% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| PTGXProtagonist Therapeutics, Inc | September 30, 2023 | +634.9% | $7.7M |
| TVTXTravere Therapeutics, Inc. | September 30, 2023 | +535.5% | $8.4M |
| RCUSArcus Biosciences, Inc. | March 31, 2025 | +292.7% | $2.5M |
| XERSXeris Biopharma Holdings, Inc. | December 31, 2023 | +237.0% | $8.4M |
| GOOGAlphabet Inc-Cl C | December 31, 2021 | +144.2% | $32.3M |
| JPMJPMorgan Chase & Co. | December 31, 2021 | +106.7% | $5.9M |
| CNQCanadian Natural Resources Limited | December 31, 2021 | +87.0% | $664K |
| TGTXTG Therapeutics, Inc. | December 31, 2025 | +84.3% | $3.7M |
| Alkermes PLCCUSIP G01767105 | June 30, 2025 | +83.1% | $6.4M |
| VERAVera Therapeutics, Inc. | March 31, 2025 | +78.6% | $1.1M |
Sold off last quarter
- Catalyst Pharmaceuticals, Inc.CUSIP 14888U101 was $3.0M
- Arcellx IncCUSIP 03940C100 was $2.2M
- CYTKCytokinetics, Incorporated was $1.6M
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $1.5M
- ADMAADMA Biologics, Inc. was $542K
- Biohaven Pharmaceutical Holding Co. LtdCUSIP G111OE107 was $514K
- EOLSEvolus, Inc. was $408K
- LENZLENZ Therapeutics, Inc. was $309K
- DuPont de Nemours, Inc.CUSIP 26614N102 was $173K
- JSPRJasper Therapeutics, Inc. was $141K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +14.5% | +14.8% |
| March 31, 2026 | +10.0% | −4.6% |
| December 31, 2025 | +13.1% | +2.4% |
| September 30, 2025 | +14.2% | +7.8% |
| June 30, 2025 | +6.1% | +10.5% |
| March 31, 2025 | −18.0% | −4.6% |
| December 31, 2024 | +11.7% | +2.1% |
| September 30, 2024 | +6.6% | +5.4% |
| June 30, 2024 | +2.9% | +4.0% |
| March 31, 2024 | +1.8% | +10.0% |
| December 31, 2023 | +5.6% | +11.2% |
| September 30, 2023 | +3.8% | −3.6% |
| June 30, 2023 | +3.5% | +8.3% |
| March 31, 2023 | +6.0% | +7.0% |
| December 31, 2022 | +11.3% | +7.1% |
| September 30, 2022 | +1.9% | −5.3% |
| June 30, 2022 | −14.7% | −16.5% |
| March 31, 2022 | −4.2% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Knott David M Jr Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1892770&type=13F-HR&dateb=&owner=include&count=40CIK 1892770
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1892770/000110465926094536/Filed August 12, 2026 · accession 0001104659-26-094536